Signalling by EGF receptor in human cancers: Accentuate the positive, eliminate the negative.
About this Book: The epidermal growth factor (EGF) receptor and its downstream signal transduction networks have been implicated in the ontology and maintenance of tumor tissues, which has motivated the discovery and development of molecularly targeted anti-EGFR therapies. Edited by John Haley and William J. Gullick, EGFR Signaling Networks in Cancer Therapy, is separated into two sections. The first of which probes the molecular pathways and the intersection of signaling networks which are frequently deregulated in human cancers, with a view to describing EGF receptor in a tumor tissue specific context. Meanwhile, the second section illustrates the many ways in which EGF receptor contribute to abnormal survival and migration signaling in cancer cells and to epithelial to mesenchymal transition and metastasis. The book also describes the mitogenic, survival, adhesive and migratory pathways within a framework of interacting subsystems that contribute to the activity and physiological regulation of the receptor in normal and neoplastic tissues. Even though there is still much to learn, this volume explores this fascinating system with compelling information.
|Authors||Bennett, H.L.; Brummer, T.; Timpson, P.; Patterson, K.I.; Daly, R.J.|
|Responsible Garvan Author|
|Publisher Name||Cancer Drug Discovery and Development EGFR Signaling Networks in Cancer Therapy|
|URL link to publisher's version||http://www.springerlink.com/content/un6881170p36l852/|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/10166|